Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Gutman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Proteome Research|August 9, 2005
Introduction to the Food and Drug Administration (FDA) regulatory processJoseph L Hackett, Steven I Gutman
The Journal of Molecular Diagnostics : JMD|February 1, 2005
Food and Drug Administration regulation of in vitro diagnostic devicesElizabeth Mansfield, Timothy J O'Leary, Steven I Gutman
Diabetes Technology & Therapeutics|February 3, 2005
Consumers report glucose meter problems to FDASteven I Gutman, Janie G Fuller, Ethan D Hausman
Expert Review of Molecular Diagnostics|September 10, 2005
FDA perspectives on pharmacogenetic testingCourtney C Harper, Reena Philip, Max Robinowitz, et al.
Human Genomics|February 8, 2006
FDA perspectives on potential microarray-based clinical diagnosticsZivana Tezak, Daya Ranamukhaarachchi, Estelle Russek-Cohen, et al.
Journal of the National Cancer Institute|October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopmentSheila E Taube, Gary M Clark, Janet E Dancey, et al.
Nature Genetics|November 28, 2002
Medical applications of microarray technologies: a regulatory science perspectiveEmanuel F Petricoin, Joseph L Hackett, Lawrence J Lesko, et al.
Biosensors & Bioelectronics|February 14, 2006
Point-of-care biosensor systems for cancer diagnostics/prognosticsSteven A Soper, Kathlynn Brown, Andrew Ellington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancerDavid R Parkinson, Robert T McCormack, Susan M Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Proteome Research|August 9, 2005
Introduction to the Food and Drug Administration (FDA) regulatory processJoseph L Hackett, Steven I Gutman
The Journal of Molecular Diagnostics : JMD|February 1, 2005
Food and Drug Administration regulation of in vitro diagnostic devicesElizabeth Mansfield, Timothy J O'Leary, Steven I Gutman
Diabetes Technology & Therapeutics|February 3, 2005
Consumers report glucose meter problems to FDASteven I Gutman, Janie G Fuller, Ethan D Hausman
Expert Review of Molecular Diagnostics|September 10, 2005
FDA perspectives on pharmacogenetic testingCourtney C Harper, Reena Philip, Max Robinowitz, et al.
Human Genomics|February 8, 2006
FDA perspectives on potential microarray-based clinical diagnosticsZivana Tezak, Daya Ranamukhaarachchi, Estelle Russek-Cohen, et al.
Journal of the National Cancer Institute|October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopmentSheila E Taube, Gary M Clark, Janet E Dancey, et al.
Nature Genetics|November 28, 2002
Medical applications of microarray technologies: a regulatory science perspectiveEmanuel F Petricoin, Joseph L Hackett, Lawrence J Lesko, et al.
Biosensors & Bioelectronics|February 14, 2006
Point-of-care biosensor systems for cancer diagnostics/prognosticsSteven A Soper, Kathlynn Brown, Andrew Ellington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancerDavid R Parkinson, Robert T McCormack, Susan M Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Pageof 1